SecBot SecBot

STIM drug pipeline

Neuronetics, Inc. · 1 rated drug
$1.25
−10.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved / Commercialized
Time to marketAlready commercialized. NeuroStar has been FDA-cleared and marketed since 2008 for adult MDD, with additional indications (OCD, adolescent MDD, anxious depression) added through subsequent 510(k) clearances, most recently in March 2024.

NeuroStar transcranial magnetic stimulation system Updated Nov 6

What to watch

The next catalyst for STIM is the Q4 2026 earnings report, expected in early February 2027, which will show whether the company can sustain its return to operating profitability and positive adjusted EBITDA. The integration of the TrakStar platform with AdvancedMD (scheduled for Q4 2026) and any updates on the Greenbrook clinic expansion and COMP360 collaboration readiness are also worth watching. There is no binary FDA decision or pivotal readout on the horizon since NeuroStar is already fully commercialized.

Bull case
  • NeuroStar is the leading TMS system for depression with over 6.1 million treatments delivered and the largest clinical dataset of any TMS system, backed by FDA clearances across MDD, anxious depression, OCD, and adolescent MDD.
  • The company returned to operating profitability in Q3 2026 with $541K in operating income and $1.9M in positive adjusted EBITDA, a significant improvement from a $7.3M operating loss a year earlier.
  • Analyst consensus is strongly bullish: 9 Buy/Strong Buy ratings vs. 1 Hold and 0 Sell, with a mean price target of $5.75, implying roughly 112% upside from the recent $2.43 close.
Bear case
  • Revenue growth is slowing in the core NeuroStar system business (only +1.8% in Q3 2026), with Greenbrook clinic revenue (+20.1%) doing the heavy lifting, which shifts the revenue mix and raises questions about the durability of the device sales model.
  • Major institutional holders including BlackRock (-74% of shares), State Street (-65%), and Geode Capital (-52%) all trimmed their STIM positions significantly in Q2 2026, signaling a lack of conviction from large passive and active managers.
  • The TMS market faces growing competition from BrainsWay (Deep TMS), MagVenture, and Magstim, and competitors have also received FDA clearance for adolescent MDD, eroding NeuroStar's first-mover advantage in that demographic.